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Abstract
Tricuspid regurgitation (TR) is a very frequent manifestation of valvular heart disease. It may be due to the primary involvement of the valve
or secondary to pulmonary hypertension or to the left-sided heart valve disease (most commonly rheumatic and involving the mitral
valve). The pathophysiology of secondary TR is complex and is intrinsically connected to the anatomy and function of the right ventricle.
A systematic multimodality approach to diagnosis and assessment (based not only on the severity of the TR but also on the assessment of
annular size, RV function and degree of pulmonary hypertension) is, therefore, essential. Once considered non-important, treatment of
secondary TR is currently viewed as an essential concomitant procedure at the time of mitral (and, less frequently, aortic valve) surgery.
Although the indications for surgical management of severe TR are now generally accepted (Class I), controversy persists concerning the
role of intervention for moderate TR. However, there is a trend for intervention in this setting, especially at the time of surgery for left-
sided heart valve disease and/or in patients with significant tricuspid annular dilatation (Class IIa). Currently, surgery remains the best
approach for the interventional treatment of TR. Percutaneous tricuspid valve intervention (both repair and replacement) is still in its in-
fancy but may become a reliable option in future, especially for high-risk patients with isolated primary TR or with secondary TR related to
advanced left-sided heart valve disease.
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INTRODUCTION
Tricuspid regurgitation (TR) is one of the most common mani-
festations of valvular heart disease (VHD) and may affect 65–85%
of the population [1, 2]. Although minimal or mild TR may be a
normal variant in structurally normal valves, moderate-to-severe
TR is usually pathological and arises as a result of leaflet abnor-
malities and/or annular dilatation [3].
Primary (organic) TR implies pathology of the tricuspid valve
(TV) complex and may be of rheumatic, degenerative, congenital,
infectious, traumatic or iatrogenic (usually secondary to pace-
maker leads) origin. Secondary (or functional) TR is far more
common and related to right ventricular (RV) dilatation and/or
dysfunction, annular dilatation and leaflet tethering, which are, in
turn, usually secondary to left-sided VHD (especially affecting
the mitral valve) [4], atrial fibrillation or pulmonary hypertension
[5, 6].
Historically, functional TR was usually treated conservatively
(i.e. no surgery), based on the misconception that it improved
after surgery of the primary left-sided VHD. However, recent
studies have shown that TR progresses in a significant number of
patients subsequent to and despite successful treatment of left-
sided valve lesions [7]. Furthermore, chronic RV overload is asso-
ciated with the development of irreversible RV dysfunction,
whose prognosis is related to the severity of associated TR. As a
consequence, the importance of TV repair at the time of left-
sided valve surgery has gained acceptance in recent years [2].
The optimal timing of surgery for isolated TR remains contro-
versial, and operation is commonly undertaken at a late stage,
because many patients remain asymptomatic (despite impaired
RV function) or present high surgical risk as a result of comorbid-
ities and/or older age [2, 3, 5]. A further contentious issue relates
to the techniques of TV surgery, because different repair methods
have been proposed. Furthermore, various percutaneous
approaches have been developed for use in high-risk patients in
recent years [6, 7].
Recent international guidelines on VHD [European Society of
Cardiology (ESC) and American Heart Association (AHA)/ACC]
contain sparse recommendations regarding the diagnosis and
treatment of TR [8, 9]. In this position paper, the European
Society of Cardiology Working Groups on Cardiovascular Surgery
and Valvular Heart Disease review the literature and attempt to
address the most frequent questions concerning this condition
that has recently drawn increasing attention. Our conclusions are
intended to complement the broader recommendations provided
by international guidelines (whose content we fully endorse).
ANATOMY AND FUNCTION OF THE TRICUSPID
VALVE
The TV separates the right atrium and ventricle and is composed
of 3 leaflets: anterior, posterior and septal (in decreasing order of
size and in a clockwise direction as seen by the surgeon), within
a partial fibrous annulus, which is part of the fibrous skeleton of
the heart. Occasionally, there may be additional (accessory) leaf-
lets. Each leaflet is connected to the homonymous papillary
muscle, although an individual septal papillary muscle is often
non-existent and replaced by small muscle heads arising directly
from the interventricular septum. Valve function is complex and
involves the chordae tendineae, papillary muscles and the right
atrial and ventricular myocardium [10].
The tricuspid annulus has a non-planar (3D), elliptical shape
in healthy individuals. The posteroseptal part is ‘lowest’ and
deviated towards the RV apex, whereas the anteroseptal part is
‘highest’ and closer to the RV outflow tract and aortic valve.
The shape and size of the annulus change during the cardiac
cycle. In functional TR, the annulus becomes planar, dilating
primarily in the direction of the anteroposterior commissure
resulting in a more circular shape (the septal annulus is part of
the cardiac fibrous skeleton and relatively spared) [11].
The more severe the TR, the more planar and circular the
annulus becomes. Progressive TR begets further RV dilatation
that, in turn, leads to RV failure (see Imaging the tricuspid valve
section).
The TV is closely related to 2 important structures that can be
injured at the time of intervention. The bundle of His crosses the
septal segment of the tricuspid annulus approximately 5 mm
from the anteroseptal commissure. At this point, the bundle
penetrates posteriorly beneath the membranous septum to reach
the crest of the muscular septum. Of equal importance, the right
coronary artery runs in the right atrioventricular groove, a few
millimetres from the descending (anteroposterior) segment of
the tricuspid annulus.
AETIOLOGY OF TRICUSPID REGURGITATION
TR may be a consequence of primary (organic) pathology of the
valve leaflets or, more commonly, a secondary consequence of
dilatation of the RV and tricuspid annulus in the context of pul-
monary hypertension and RV failure [12].
Primary tricuspid regurgitation
Worldwide, rheumatic fever remains the most frequent cause of
primary TV disease, leading to scarring of the valve leaflets and/or
chordae with resulting restriction of leaflet mobility. Combined
stenotic and regurgitant lesions of varying degrees of severity are
not infrequently encountered (often in association with mitral
valve disease), whereas isolated tricuspid stenosis or pure isolated
TR are rare. The annulus is usually dilated [13].
Primary TR may also be of congenital origin, either as an iso-
lated lesion or in association with atrioventricular canal defects,
aneurysms of the ventricular septum or as a component of
Ebstein’s anomaly. TV prolapse as a result of myxomatous change
of the valve leaflets and chordae tendinae is relatively unusual
and often associated with similar changes affecting the mitral
valve, and with atrial septal defects.
Primary TR is a common manifestation of carcinoid syndrome,
where white fibrous carcinoid plaques develop on the endocar-
dium of valve cusps and cardiac chambers, and on the intima of
the great veins and coronary sinus. These have a propensity for
the ventricular surfaces of the valve, resulting in adherence of the
leaflets to the RV free wall [14].
Another common acquired cause of primary TR is infective
endocarditis (most frequently seen in intravenous drug addicts
with staphylococcal infection or in patients with pacing or device
leads) [15, 16]. Rarer causes include drugs (methysergide and
pergolide), cardiac tumours (particularly right atrial myxoma),
endomyocardial fibrosis and systemic lupus erythematosus.
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Secondary tricuspid regurgitation
Secondary TR, the most prevalent tricuspid pathology, may be
observed in patients with RV pressure overload secondary to any
form of cardiac or pulmonary vascular disease and reflects the
presence and severity of RV failure. The most common causes
are left-sided VHD (particularly mitral but increasingly also
aortic), primary or secondary pulmonary hypertension, persistent
atrial fibrillation (with tricuspid annular dilatation), RV ischaemia
and cardiomyopathy.
Secondary TR is most commonly associated with rheumatic
VHD but may also result from degenerative and ischaemic mitral
valve disease as a consequence of pulmonary hypertension and
RV volume overload. Long-standing, persisting atrial fibrillation
may also lead to TR secondary to annular dilatation [17].
PATHOPHYSIOLOGY OF THE RIGHT VENTRICLE
IN ASSOCIATION WITH TRICUSPID
REGURGITATION
The relationship between TR and the RV is complex and differs ac-
cording to the mechanism of TR. Primary TR causes pure volume
overload on initially normal right-sided cardiac chambers [3].
Conversely, RV enlargement is the major cause of secondary TR,
through tricuspid annular dilatation and valve tenting [18]. The se-
verity of functional TR and RV dilatation is strongly correlated with
the presence of leaflet tethering (but less so with annular diameter
which reflects leaflet size rather than valve function). Annular dila-
tation appears to be a secondary consequence of RV dilatation.
The interplay of echocardiographic and cardiac magnetic reson-
ance imaging remains poorly defined (see below) and is the sub-
ject of ongoing investigation.
RV enlargement is most often the consequence of increased
afterload due to pulmonary hypertension, usually post-capillary
pulmonary hypertension (defined as pulmonary artery wedge
pressure >15 mmHg), reflecting increased left-side filling pres-
sures. Precapillary pulmonary hypertension (defined as pulmon-
ary artery wedge pressure >_15 mmHg with pulmonary vascular
resistance >3 Wood units) is most often due to intrinsic lung dis-
eases or pulmonary thromboembolism [19].
The RV has less muscle mass than the left ventricle, and RV sys-
tolic function is therefore more load sensitive. Thus, pulmonary
hypertension results in an early fall in RV ejection fraction and
associated RV enlargement [20]. Initial pressure overload thereby
rapidly translates into mixed pressure and volume overload, pro-
gressive RV dilatation and secondary TR—a vicious circle, because
TR itself contributes to further RV enlargement, thereby increas-
ing tenting and TR severity [21]. Less frequently, secondary TR
may be due to RV enlargement without increased afterload (idio-
pathic secondary TR) [18].
The severity of secondary TR and its RV consequences may be
partly reversible after correction of the primary cause (particu-
larly in the case of left-sided VHD) [22]. However, RV dysfunction
may be irreversible and even initial impairment of RV function is
a strong independent predictor of survival after left-sided valve
surgery [23]. Increased RV volumes are also associated with
reduced survival in isolated TR [24]. Although RV volume thresh-
olds have been defined for predicting the recovery of RV impair-
ment due to pulmonary regurgitation in congenital heart disease
[25], no comparable thresholds have been defined for secondary
TR [6]. RV enlargement is also responsible for complex inter-
actions with the left ventricle, and left ventricular impairment
may itself lead to reduced RV stroke volume [26].
Patients with heart failure and preserved ejection fraction may
present with diastolic dysfunction, atrial fibrillation and varying
degrees of TR, which have independent prognostic impact [27].
Finally, a ‘restriction-dilatation syndrome’ occurs when systolic
function ‘fails’; diastolic pressure raises and the interventricular
septum moves towards the left ventricle during diastole, which in
turn raises the left ventricular diastolic pressure and perpetuates
TR [20, 28–30].
CLINICAL PRESENTATION AND NATURAL
HISTORY
TR is often clinically silent and symptoms usually relate to con-
comitant left-sided VHD. General fatigue and reduced exercise
capacity may occur as a result of low cardiac output, and upper
abdominal pain may accompany hepatic congestion. Peripheral
lower limb oedema may be present in advanced cases and cause
significant discomfort.
Typical signs on auscultation are a soft pansystolic murmur at
the lower sternal border and xiphoid process, typically increasing
in intensity during inspiration. However, these signs are non-
specific and may be difficult to identify. Signs of right heart
failure are present in advanced TR: systolic jugular distension,
pulsatile hepatomegaly and peripheral oedema. Ascites, liver fail-
ure and cachexia may be observed in end-stage disease [12].
The electrocardiogram frequently shows right bundle branch
block and atrial fibrillation reflects disease evolution. The chest
X-ray shows cardiomegaly secondary to right atrial and ventricu-
lar enlargement.
Isolated primary TR evolves slowly but is associated with ex-
cess mortality in comparison with the general population. The
10-year incidence of dyspnoea or congestive heart failure was
estimated at 57% in asymptomatic patients and strongly related
to RV enlargement [31]. Similarly, RV dysfunction, TR severity and
increasing pulmonary artery pressure are factors predicting sur-
vival in isolated TR [32].
Secondary TR is frequently associated with left-sided VHD,
which is the most important determinant of prognosis.
Nevertheless, TR has a prognostic value per se that is proportional
to its severity, even after adjustment for left ventricular function
and pulmonary artery pressure [33]. Secondary TR may improve
after correction of left-sided VHD but may also persist or even
worsen [34]. This evolution is unpredictable, and severe late TR is
associated with reduced survival [35, 36]. Isolated secondary TR is
less frequent and prognosis strongly depends on TR severity (10-
year survival 38% vs 70% in those with severe and non-severe TR,
respectively) [24].
IMAGING THE TRICUSPID VALVE
The goals of imaging in patients with TR are the assessment of se-
verity, aetiology and consequences (e.g. RV size and function,
pulmonary artery dimension and pressure) and the detection of
concomitant left-sided VHD (including the assessment of pros-
thetic valve function, where appropriate).
Echocardiography is the principal imaging modality for the as-
sessment of valve morphology and grading TR (Table 1). Routinely,
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only 2 leaflets can be seen simultaneously using a standard 2D
view. Evaluation with 3D imaging is a useful tool [37], allowing sim-
ultaneous imaging of all 3 leaflets and commissures.
Trivial/mild TR is frequently encountered in normal people.
This so-called ‘physiological’ TR is characterized by normal leaflet
morphology and a thin, central TR colour jet adjacent to valve
closure [38]. Secondary TR is a consequence of tricuspid annular
dilatation and leaflet tethering [39], and quantitation of these par-
ameters is useful to predict TR. 2D echocardiographic evaluation
of the annular diameter underestimates the actual size due to its
elliptical shape. Consequently, the annular diameter measured in
a 4-chamber (septal–lateral) view or a short-axis view (oblique) is
less than the true anteroposterior diameter [37]. In adults, the
normal tricuspid annular diameter is 28 ± 5 mm (4-chamber view
in diastole). Current ESC/EACTS guidelines suggest a threshold
diameter >_40 mm (>21 mm/m2) as an indicator for surgery [40].
The severity of the TR changes during the respiratory cycle due
to inspiratory increase in RV size and change of morphology,
resulting in tricuspid annular dilatation and leaflet tethering [41].
A difference in the peak TR velocity between inspiration and ex-
piration >_0.6 m/s is associated with severe TR (sensitivity of 66%
and specificity of 94%) [42].
Increased apical displacement of the tricuspid leaflets (tether-
ing) is evaluated by measuring the tenting area (area between the
atrial surface of the leaflets and the annular plane at maximal sys-
tolic closure) and coaptation distance (distance between the an-
nular plane and point of coaptation) in the 4-chamber view [38].
A tenting area >1 cm2 and coaptation depth <8 mm are associ-
ated with severe TR [39].
Right heart catheterization should be considered to measure pul-
monary artery pressures when laminar TR precludes reliable
Doppler-derived estimation. Cardiac magnetic resonance (CMR)
provides more accurate evaluation of the RV complementary infor-
mation to echocardiography, including calculation of regurgitant
volume and fraction, mean and peak velocity or transvalvular gradi-
ent [43]. The regurgitant orifice is estimated by cine imaging
through the leaflet tips in systole or by visualization of the flow jet
in cross-section through plane phase-contrast velocity mapping.
The regurgitant volume is estimated by calculating RV stroke vol-
ume and pulmonary forward flow. If TR is the only valve lesion, the
difference between right and left ventricular stroke volumes may be
used to estimate regurgitant volume [44].
Multislice computed tomography offers detailed anatomical
evaluation of the TV due to its excellent spatial resolution and is
especially useful in patients with complex congenital heart dis-
ease [45]. This technique involves the use of ionizing radiation
and should only be used when the same amount of information
cannot be obtained using non-radiation techniques.
Intraoperative echocardiographic assessment
The diagnosis of TR and decision to intervene must be made pre-
operatively. Severity of TR is influenced by fluid loading and the pre-
vailing intraoperative conditions, including the effects of anaesthesia.
Although intraoperative transoesophageal echocardiography is es-
sential for the assessment of mitral and/or aortic valve dysfunction,
it may also underestimate the severity of TR and lead to incorrect
decisions regarding the need for intervention [46]. Hence, the recent
trend towards greater reliance on tricuspid annular diameter
(>40 mm or >21 mm/m2 in the 4-chamber view) to determine
whether a concomitant tricuspid annuloplasty is indicated.
EVALUATING RIGHT VENTRICULAR FUNCTION
Despite the limitations of 2D echocardiography in evaluating RV
function because of geometric assumptions [47], complete
Table 1: Echocardiographic grading of the severity of TR
Parameters Mild Moderate Severe
Qualitative
TV morphology Normal/abnormal Normal/abnormal Abnormal/flail/large coaptation defect
Colour flow TR jet Small, central Intermediate Very large central jet or eccentric wall impinging jet
CW signal of TR jet Faint/parabolic Dense/parabolic Dense/triangular with early peaking (peak <2 m/s in massive TR)
Semi-quantitative
VC width (mm)a Not defined <7 >7
PISA radius (mm)b <_5 6–9 >9
Hepatic vein flowc Systolic dominance Systolic blunting Systolic flow reversal
Tricuspid inflow Normal Normal E-wave dominant (>_1 m/s)d
Quantitative
EROA (mm2) Not defined Not defined >_40
R Vol (ml)e Not defined Not defined >_45
An IVC diameter <2.1 cm is considered normal.
aAt a Nyquist limit of 50–60 cm/s.
bBaseline Nyquist limit shift of 28 cm/s.
cUnless other reasons of systolic blunting (atrial fibrillation or elevated RA pressure).
dIn the absence of other causes of elevated RA pressure.
eThe RA, RV size and IVC are usually of normal size in patients with mild TR. An end-systolic RV eccentricity index >2 suggests severe TR. In acute severe TR,
the RV size is often normal. In chronic severe TR, the RV is classically dilated. Accepted cut-off values for non-significant right-sided chambers enlargement
(measurements obtained from apical 4-chamber view): mid RV cavity diameter <_33 mm, RV end-diastolic area <_28 cm2, RV end-systolic area <_16 cm2, RV
fractional area change >32%, maximal 2D RA volume <_33 ml/m2.
CW: continuous-wave; EROA: effective regurgitant orifice area; IVC: inferior vena cava; PISA: proximal isovelocity surfasse area; RA: right atrium; RV: right
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assessment of RV geometry and function is usually achievable
using 3D echocardiography and CMR. 3D echocardiography cor-
relates well with CMR and has less propensity to underestimate
end-diastolic and end-systolic volumes and superior reproduci-
bility to 2D imaging [48]. However, 3D-derived RV volumes are
slightly smaller than those obtained with CMR with a lower refer-
ence limit of 44% for RV ejection fraction, and upper limits of
89 ml/m2 and 45 ml/m2 for RV end-diastolic and end-systolic
volumes, respectively [49].
In clinical practice, the simplest method used to screen RV dilata-
tion is by measurement of ventricular (end-diastolic and end-
systolic) areas and linear dimensions (basal and mid-cavity plus RV
outflow tract proximal and distal diameters) in end diastole [49].
Adjustment of the apical 4-chamber view by rotation of the probe
over the cardiac apex is important to avoid foreshortening and de-
rive the maximal RV diameter. Basal diameter >42 mm, mid-cavity
diameter >33 mm or apex-to-base length >86 mm indicate RV en-
largement [49]. Qualitative assessment of RV function may be
derived by geometric evaluation of the inter-ventricular septum
whose patterns of movement in systole and diastole can help distin-
guish between volume and pressure overload [50]. In pure volume
overload (as in severe TR), the septum flattens in diastole and pushes
against the left ventricle as a result of increased RV end-diastolic
pressure. In systole, left ventricular pressure remains higher than that
in the RV and the septum regains its normal configuration.
The fractional area change is the percentage change in RV
chamber area during the cardiac cycle measured from the apical
4-chamber view. Fractional area change (normal >35%) correlates
with RV ejection fraction measured using CMR [49]. The rate of
RV pressure rise in systole (RV dP/dt) provides an estimate of RV
systolic function and can be derived from the descending slope
of the TR continuous-wave Doppler signal, a value <400 mmHg/s
indicates RV dysfunction [49].
Tricuspid annular plane systolic excursion (TAPSE) assesses the
degree of tricuspid annular displacement towards the apex and
accurately reflects RV longitudinal function [51]. Current ESC/
EACTS guidelines recommend the use of tricuspid annular plane
systolic excursion (<15 mm), tricuspid annular systolic velocity
(<11 cm/s) and RV end-systolic area (>20 cm2) to identify patients
with RV dysfunction [8]. However, these values may underesti-
mate the extent of RV dysfunction in the presence of severe TR
with volume overload and should be interpreted with caution.
CMR has been considered the gold standard technique to
evaluate the left (LV) and right ventricular (RV) volumes and ejec-
tion fraction, and both parameters independently predict signifi-
cant residual TR after surgery [52]. Although there are no defined
thresholds in terms of RV volumes or ejection fraction to indicate
surgery in patients with TR, an RV end-diastolic volume >_64 ml/
m2 predicts RV dysfunction at follow-up.
INDICATIONS FOR TRICUSPID VALVE
INTERVENTION
Although significant TR with progressive RV dilatation and dys-
function may remain clinically silent for a prolonged period and
compromise individual patient outcome, the timing of surgical
intervention for TR remains controversial [38]. In a recent meta-
analysis, Pagnesi et al. [53] demonstrated that concomitant TV re-
pair at the time of left-sided valve surgery is associated with
reduced cardiovascular mortality and improved TR-related out-
comes (as assessed by echocardiography) at follow-up.
Both European (ESC/EACTS) and American (AHA/ACC)
guidelines state that isolated TV surgery is indicated in symptomatic
patients with severe primary TR (Class I) and should be con-
sidered in asymptomatic or mildly symptomatic patients with RV
enlargement or deteriorating RV function (Class IIa) [8, 9].
Although such patients respond well to diuretic therapy, delayed
surgery is likely to result in irreversible RV damage, organ failure
and poor results of later surgical intervention.
TV surgery is recommended for patients with severe TR
undergoing left-sided valve surgery, irrespective of symptoms
(Class I). Although there is no specific evidence to confirm that
mild TR progresses to severe TR with or without repair, TV sur-
gery should be considered (Class IIa) in patients with mild/mod-
erate secondary TR and/or significant annular dilatation (>_40 mm
or 21 mm/m2) (Class IIa) [8, 9].
Early surgery should also be considered for severe TR occurring
late after left-sided valve surgery (with or without original TV inter-
vention) (Class IIa) in symptomatic patients and in those who are
asymptomatic but with progressive RV dilatation or dysfunction
(unless severe right/left ventricular dysfunction or pulmonary vas-
cular disease preclude surgery). Late referral is associated with
poor outcomes, because RV dysfunction is already established in
many patients [54].
SURGICAL TECHNIQUES
The principles of TV reconstruction are identical to those for mi-
tral valve repair—restoration of full leaflet mobility, correction of
prolapse, provision of a large leaflet coaptation surface and an-
nular stabilization.
Access to the TV is usually via median sternotomy (although
right thoracotomy may be better for redo surgery and some
groups routinely employ minimally invasive right thoracotomy)
[55]. TV surgery is usually performed under cardioplegia, al-
though beating-heart surgery (even for first-time operations)
may prevent atrioventricular block and reduce ischaemic time
(both of which may be of particular value in high-risk patients
undergoing TV replacement late after left-sided valve surgery).
Tricuspid annuloplasty techniques: sutures, rings
and bands
Annuloplasty techniques are well established and share the com-
mon goal of narrowing the valve orifice to achieve leaflet coapta-
tion [56, 57]. The De Vega annuloplasty is still used by many
surgeons and consists of a double circular suture of the anterior
and posterior annulus to narrow the orifice to the desired dimen-
sion, and several modifications of the technique are in use
[58, 59]. Avoidance of the use of prosthetic material is an advan-
tage, particularly in cases of active endocarditis, although the
technique does not restore normal annular shape. Recently, the
concept of TV orifice index to optimize TV annular reduction has
been developed [60].
A variety of prosthetic oval-shaped rings have therefore been
developed to replicate the systolic configuration of the normal
tricuspid orifice. The prosthetic ring should be carefully sized to
correspond to leaflet and body surface area, but it should be fur-
ther downsized if there is severe leaflet tethering.
Sutures must be placed in the annulus, 1–2 mm beyond the
leaflet hinge line. Care should be taken to avoid the adjacent
1026 M.J. Antunes et al. / European Journal of Cardio-Thoracic Surgery
Downloaded from https://academic.oup.com/ejcts/article-abstract/52/6/1022/4086168
by Graulich ULg user
on 23 January 2018
aortic valve and right coronary artery, and the last sutures should
be placed in the anteroseptal commissure (right fibrous trigone)
and in the middle of the septal annulus to avoid injury to the
bundle of His.
Additional procedures (e.g. anterior leaflet enlargement and
artificial polytetrafluoroethylene chordae) may be useful in spe-
cific settings and when the valve is significantly deformed [61]. All
techniques should be adapted in the presence of pacemaker
leads according to anatomy, the patient’s condition and the sur-
geon’s experience.
Tricuspid valve replacement
The gold standard for the surgical treatment of secondary TR is
TV annuloplasty. However, the results are very poor in patients
with severe RV dysfunction, very large annuli and significant leaf-
let tenting (precise measurements poorly defined) who are prob-
ably better served with valve replacement.
Accurate prosthesis sizing is essential to not distort the right
coronary artery. TV replacement is usually performed using mul-
tiple pledgeted annular sutures. Sutures in the septal portion (be-
tween the middle of the septal leaflet and the anteroseptal
commissure) should be placed through leaflet tissue (with preser-
vation of the septal leaflet) to avoid injury to the bundle of His.
The use of non-everting pledgeted sutures (pledgets placed on
the ventricular aspect of the leaflet tissue) is recommended.
Results
TV repair has lower perioperative mortality than valve replace-
ment and is generally the preferred option. Mortality is low after
annuloplasty for uncomplicated primary TR, but outcomes de-
pend on aetiology, RV function and patient risk profile. Repair
for secondary TR at the time of left-sided valve surgery has no
impact on mortality, unless there is severe heart failure and/or
significant RV dilatation or dysfunction.
In contrast, repeat surgery for TR late after initial mitral (or aor-
tic) valve surgery is associated with higher morbidity and mortal-
ity, reflecting the overall clinical condition of the patient
(including age and the number of previous cardiac interventions)
[54]. Perioperative mortality rates up to 30% have been reported,
even from experienced centres [62], and long-term results may
also be poor due to associate irreversible RV or left ventricular
dysfunction.
Suture and ring annuloplasty are associated with good long-
term outcomes. Rates of late recurrent TR are higher following
the original De Vega procedure [55], with conflicting evidence
concerning long-term survival [7], although modifications of the
original suture annuloplasty technique have been associated with
encouraging results [5]. In a recent comparison, long-term mor-
tality was equivalent following the ring or the De Vega suture
annuloplasty in patients undergoing TV repair at the time of
mitral valve surgery and predicted by the presence of diabetes
mellitus, baseline RV dysfunction and older age. The rates of
durable repair and recurrent TR were similar over long-term
follow-up [63]. Rigid ring dehiscence is also a potential late
complication [64].
Outcomes with mechanical and bioprosthetic valves are simi-
lar if TV replacement is necessary [65], although the use of a
bioprosthetic valve is currently preferred (perhaps reflecting the
emerging possibility of percutaneous valve-in-valve implantation
for late prosthetic valve degeneration) [66].
Ten-year survival rate ranges from 30% to 50%, and late mor-
tality is predicted by preoperative functional class, the LV and RV
function and prosthesis-related complications [62, 67, 68].
Transcatheter interventions
New transcatheter solutions for the treatment of TR are now
emerging, most of which are still in development or in the initial
phase of clinical application. Some devices mimic leaflet edge-
to-edge repair (MitraClip), whereas others replicate partial suture
annuloplasty (Mitralign, 4-Tech).
Experience with these devices is extremely preliminary, and
the safety and efficacy of the devices are yet to be fully demon-
strated. A role in patients with less-than-severe secondary TR
due to left-sided valve disease therefore seems unlikely for
the foreseeable future. Most patients will remain surgical
candidates, because both left- and right-sided VHD will require
treatment using the most effective surgical approaches. On the
other hand, transcatheter options are likely to be highly
appropriate in high-risk or inoperable patients with functional
mitral and TR, where percutaneous treatment to both valves
could be considered simultaneously or using a staged approach
[69].
Late TR following previous left-sided valve surgery in high-risk
patients (e.g. with renal and/or hepatic impairment, and severe
RV dysfunction) might potentially benefit from less invasive
transcatheter therapy [24, 70].
Finally, it should be recognized that current transcatheter de-
vices are unable to provide complete durable correction of TR in
its advanced stages with severe annular dilatation and leaflet
tethering due to significant RV dilatation and dysfunction.
CONCLUSIONS
1. Primary TR is rare and caused by the abnormalities of the TV
apparatus. Secondary TR is far more frequent and related to
RV pressure and/or volume overload and dysfunction, result-
ing in annular dilatation and/or leaflet tethering.
2. The pathophysiology of TR is complex. A systematic multi-
modality approach to diagnosis and assessment (based not
only on TR severity but also on assessing annular size and RV
function) is, therefore, essential.
3. Clinical presentation ranges from subtle manifestations in the
asymptomatic patient to overt right heart failure. Diuretic
therapy rapidly decreases volume overload but may mask
symptoms and signs of RV dysfunction.
4. Physical examination is a key to diagnosis, and echocardiog-
raphy remains the principal imaging tool. CMR and invasive
haemodynamic assessment provide essential supplementary
information.
5. The severity of TR is influenced by loading conditions and
usually underestimated by transoesophageal echocardiog-
raphy performed under general anaesthesia—the decision to
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assessment. If this is not possible then greater reliance should
be placed upon intraoperative measurement of tricuspid an-
nular diameter rather than intraoperative assessment of the
degree of regurgitation.
6. TV surgery is recommended in patients with severe primary
or secondary TR. Surgery should also be considered for
patients with mild or moderate secondary TR and a
dilated tricuspid annulus (diameter >_40 mm in the echo-
cardiographic 4-chamber view), who are undergoing
surgery for left-sided VHD.
7. At this stage, TV surgery is not recommended in patients
with annular dilatation but no (or minimal) TR.
8. Patients with severe TR after previous left-sided valve surgery
need careful follow-up to detect the need for early redo
surgery (or percutaneous intervention) before the develop-
ment of significant RV dilatation and/or dysfunction.
9. Future developments in percutaneous TV intervention may
offer new treatment options in selected cases.
RECOMMENDATIONS
The ESC Working Groups of Cardiovascular Surgery and Valvular
Heart Disease recommend the diagnostic and management algo-
rithms outlined in Figs 1 and 2 for patients with primary and sec-
ondary TR, respectively.
Conflict of interest: none declared.
Figure 1: Management of primary tricuspid regurgitation. RV: right ventricular.
Figure 2: Management of secondary TR. sPAP: systolic pulmonary arterial pressure; TR: tricuspid regurgitation; TV: tricuspid valve.
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